Skip to main content
Premium Trial:

Request an Annual Quote

DNA Script, Dynamic Combinatorial Chemistry Ink Licensing Deal

NEW YORK (GenomeWeb) – DNA Script announced today that it has acquired an exclusive license from Dynamic Combinatorial Chemistry (DCC) to a novel DNA building block for use in enzymatic DNA synthesis.

The building blocks, which were initially developed by DCC affiliate Firebird Biomolecular Sciences, are reversible terminator nucleotides with cleavable protective groups that help in controlling the enzymatic synthesis process, according to DNA Script COO Sylvain Gariel.

"Modified DNA building blocks in this technology transfer were initially created for enzyme-based DNA sequencing, mutation detection, and DNA tagging and processing," DCC CEO Steven Benner, who invented the technology, said in a statement. "However, the modifications can be compatible with enzyme-based DNA synthesis — exactly the business that DNA Script leads."

Specific terms of the deal were not disclosed. However, DNA Script said that the agreement may be expanded to include the commercialization of new DCC technologies developed with National Institutes of Health funding.

In September, Paris-based DNA Script closed an €11 million Series A financing round led by Illumina Ventures.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.